December 14, 2018 — Digital health company Analytics 4 Life and Actelion Pharmaceuticals Ltd. announced a collaborative agreement to investigate the use of Analytics 4 Life’s diagnostic imaging technology in pulmonary hypertension. The first 500-person clinical study has been initiated for this serious, life-threatening condition affecting millions of people worldwide.
Analytics 4 Life seeks to use machine learning technologies to develop a more complete picture of cardiac health with a single, non-invasive test. Actelion, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, specializes in the science and treatment of pulmonary arterial hypertension (PAH), a type of pulmonary hypertension – a cardiovascular disorder with an average life expectancy of only seven to nine years once diagnosed and therapy is initiated. On average, there is a three-year delay from a patient presenting with symptoms to receiving an accurate diagnosis of PAH from right heart catheterization. The goal of this collaboration is to diagnose more patients with all types of pulmonary hypertension earlier, leading to improved outcomes.
The agreement will focus on Analytics 4 Life’s CorVista platform. CorVista is a non-invasive medical imaging system designed to acquire and process patient data and display results in a report accessible via a secure web portal. The system scans signals emitted by the body without radiation, exercise or pharmacologic stress, and wirelessly transmits the signal package to the cloud for processing and report generation. Physicians can interpret and use the results as part of an assessment of their patient.
CorVista operates on a secure, cloud-based platform amenable to clinical investigation for a myriad of cardiovascular diseases. Paired physiologic signals and clinical results from gold-standard tests are collected and wirelessly transmitted to the cloud, where machine learning analysis can be performed to develop clinically relevant algorithms that can ultimately be embedded into the CorVista system. It has already been tested in over 2,600 patients in the Coronary Artery Disease Learning and Algorithm Development (CADLAD) clinical study.
For more information: www.analytics4life.com
April 01, 2024 
